The authors of a recent study in the New
England Journal of Medicine (N Engl J Med 2012;367:725-734) screened for
autoantibodies against a series of germane immunological cytokines in a set of
severely immunodeficient adult patients in Thailand and Taiwan. The patients
were selected based on the presence of various stages of opportunistic
infection but not HIV. Notably, neutralizing anti-interferon-γ autoantibodies
were detected in 88% of adults with multiple opportunistic infections and were
associated with an adult-onset immunodeficiency akin to that of advanced HIV
infection. The applicability of these results to non-Asian populations has not
yet been determined, but these findings certain open up new possibilities for
the etiology of acquired immunodeficiency. These results also raise interesting
strategies for treatment of this new disease complex.
Drs. Jean Bousquet, MD, and Marc E. Rothenberg, MD, PhD, bring you breaking news and the latest research of interest to the allergy/immunology community.
Search This Blog
Tuesday, August 28, 2012
Tuesday, August 21, 2012
Is technology bringing a new era for our patients with anaphylaxis?
Earlier this month, the U.S. Food and
Drug Administration (FDA) approved a new epinephrine auto-injector,
Auvi-Q, for patients at risk for anaphylaxis. The
device provides audio and visual cues that lead patients or caregivers who are administering
an injection through the process, step-by-step. The hope is that this system
will improve care as surveys have shown that patients at risk of anaphylaxis do
not always know how to use their device during an emergency. Do you think this
will improve the quality-of-life of our patients with severe anaphylaxis?
Subscribe to:
Posts (Atom)